期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Current evidence of drug-elution therapy for infrapopliteal arterial disease 被引量:1
1
作者 Stavros Spiliopoulos Nikiforos Vasiniotis Kamarinos Elias Brountzoss 《World Journal of Cardiology》 CAS 2019年第1期13-23,共11页
New and sophisticated endovascular devices, such as drug-eluting stents(DES)and drug-coated balloons(DCB), provide targeted drug delivery to affected vessels. The invention of these devices has made it possible to add... New and sophisticated endovascular devices, such as drug-eluting stents(DES)and drug-coated balloons(DCB), provide targeted drug delivery to affected vessels. The invention of these devices has made it possible to address the reparative cascade of arterial wall injury following balloon angioplasty that results in restenosis. DESs were first used for the treatment of infrapopliteal lesions almost 20 years ago. More recently, however, DCB technology is being investigated to improve outcomes of endovascular below-the-knee arterial procedures, avoiding the need for a metallic scaffold. Today, level IA evidence supports the use of infrapopliteal DES for short to medium length lesions,although robust evidence that justifies the use of DCBs in this anatomical area is missing. This review summarizes and discusses all available data on infrapopliteal drug-elution devices and highlights the most promising future perspectives. 展开更多
关键词 Drug-elution therapy Infrapopliteal arterial disease CURRENT evidence drugcoated BALLOONS DRUG-ELUTING STENTS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部